Exelixis Inc (EXEL) Beats EPS Estimate with $0.82 and Reports Revenue of $628.7 Million -- Is the Stock Overvalued?
Exelixis Inc (EXEL) reported strong financial results for Q2 2026, surpassing analyst expectations with total revenues of $628.7 million and a GAAP diluted EPS of $0.82. The biopharmaceutical company, known for its cancer treatments like cabozantinib, updated its fiscal year 2026 guidance, projecting total …